AI Article Synopsis
- The article discusses landiolol, a newly approved ultra-short acting injectable beta-blocker in Europe, highlighting its pharmacokinetic and pharmacodynamic characteristics.
- It presents initial experiences from studies involving Caucasian healthy volunteers and patients with atrial fibrillation.
- In emergency situations, landiolol effectively reduces heart rate in tachycardic atrial fibrillation patients without causing significant drops in blood pressure, showing similar results in both Caucasian and Asian populations.
Article Abstract
This article provides new insight on landiolol, an ultra-short acting injectable betablocker, recently approved in Europe, with regard to its pharmacokinetic and pharmacodynamic profile, along with its first experience in Caucasian healthy volunteers and patients with atrial fibrillation. Landiolol as iv formulation exhibited in an emergency setting rapid rate reduction in patients with tachycardic atrial fibrillation without pronounced blood pressure drop both in caucasian and asian populations in similar manner.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909771 | PMC |
| http://dx.doi.org/10.1093/eurheartj/sux037 | DOI Listing |
Publication Analysis
Top Keywords
atrial fibrillation
12
emergency setting
8
landiolol pharmacology
4
pharmacology rate
4
rate control
4
control atrial
4
fibrillation emergency
4
setting article
4
article insight
4
insight landiolol
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!